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Background: Pancreatic cancer is one of the most aggressive cancers, and the aggressiveness of pancreatic cancer
is in part due to its intrinsic and extrinsic drug resistance characteristics, which are also associated with the
acquisition of epithelial-to-mesenchymal transition (EMT). Increasing evidence suggests that EMT-type cells share
many biological characteristics with cancer stem-like cells. And miR-200 has been identified as a powerful regulator
of EMT.
Methods: Cancer Stem Cells (CSCs) of human pancreatic cancer cell line PANC-1 were processed for CD24, CD44
and ESA multi-colorstaining, and sorted out on a BD FACS Aria II machine. RT-qPCR was performed using the
miScript PCR Kit to assay the expression of miR-200 family. In order to find the role of miR-200a in the process of
EMT, miR-200a mimic was transfected to CSCs.
Results: Pancreatic cancer cells with EMT phenotype displayed stem-like cell features characterized by the expression of
cell surface markers CD24, CD44 and epithelial-specific antigen (ESA), which was associated with decreased expression of
miR-200a. Moreover, overexpression of miR-200a was resulted in down-regulation of N-cadherin, ZEB1 and vimentin, but
up-regulation of E-cadherin. In addition, miR-200a overexpression inhibited cell migration and invasion in CSCs.
Conclusion: In our study, we found that miR-200a played an important role in linking the characteristics of cancer
stem-like cells with EMT-like cell signatures in pancreatic cancer. Selective elimination of cancer stem-like cells by
reversing the EMT phenotype to mesenchymal-to-epithelial transition (MET) phenotype using novel agents would
be useful for prevention and/or treatment of pancreatic cancer.
Keywords: CSC, EMT, Pancreatic cancer, miR-200aBackground
Pancreatic cancer is one of the most aggressive cancers,
which is usually diagnosed in an advanced state for
which there are few or no effective therapies [1]. One of
the major hallmarks of pancreatic cancer is its extensive
local tumor invasion and early systemic dissemination
[2]. Over the past two decades, numerous efforts have
been made in improving treatment and survival of
pancreatic cancer patients but the outcome has been
disappointing [3]. Emerging evidence suggest that the re-
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reproduction in any medium, provided the ortumor initiating cells, also classified as cancer stem-
like cells in a tumor mass. The CSCs have the cap-
acity of self-renewaland the potential to regenerate
into all types of differentiated cells giving rise to het-
erogeneous tumor cell populations in a tumor mass,
which contributes to tumor aggressiveness [4,5]. The
existence of CSCs or cancer stem-like cells in a tumor
mass is believed to be responsible for tumor recurrence
because of their intrinsic and extrinsic drug-resistance
characteristics [3].
Oct4 and Nanog are transcription factors essential
for maintaining stem cell phenotypes. Oct4 is a POU
domain-containing transcription factor. It is involved in
the regulation of cell growth and differentiation in a
variety of tissues. Nanog is a homeobox-containing tran-
scription factor. Its overexpression is associated with theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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cells. And Oct4 and Nanog expression is associated with
early stages of pancreatic carcinogenesis [6].
It has recently become clear that EMT is associated
with drug resistance and cancer cell metastasis [7]. Dur-
ing this process, the expression of E-cadherin is down-
regulated, which is a transmembrane protein essential
for the stable adherens junctions, and the expression of
the mesenchymal molecules vimentin, fibronectin, and/or
N-cadherin are up-regulated [8,9]. In pancreatic cancer
cells, EMT is also reported to be a crucial step for tumor
cell migration and invasion [10]. Recent studies have
demonstrated that EMT plays a great role not only in
tumor metastasis, but also in tumor recurrence that is
believed to be tightly linked with the biology of cancer
stem-like cells or cancer-initiating cells. However, the
mechanisms by which EMT cells generate the stem-like
cells remain to be elucidated [11-13]. Importantly, emer-
ging evidence implicated the critical role of microRNAs
because they are key regulatory molecules in bio-
logical and pathologic processes including EMT [7].
MicroRNAs are small and non-coding RNA molecules
that can regulate gene expression by interacting with
multiple mRNAs and inducing either degradation of
mRNA or inhibition of their translation to functional
proteins [7,14]. Members of the miR-200 family are
downregulated in human cancer cells and tumors due
to aberrant epigenetic gene silencing and play a crit-
ical role in the suppression of EMT, tumor cell adhe-
sion, migration, invasion and metastasis, by targeting
and repressing the expression of key mRNAs that are
involved in EMT (ZEB1 and ZEB2), and participates
in a signalling network with the E-cadherin transcrip-
tional repressors ZEB1/deltaEF1 and ZEB2/SIP1, and
TGF-β2 that is postulated to facilitate maintenance of
stable epithelial or mesenchymal states but also allow
reversible switching between these states in response
to EMT effectors (such as TGF-β) [15,16]. In ovarian
and breast cancer, low expression of miRNA-200 plays
important roles in cancer metastasis [14,17,18]. MiR-
200 changed the tumor environment, inhibiting the
process of EMT and metastasis [19,20]. These findings
hypothesizes that the expression of miR-200 in pan-
creatic cancer cell is correlated with stemness, EMT and
metastasis.
Since miR-200 is associated with EMT, which is be-
lieved to be associated with cancer stem cells or cancer
stem-like cells, we investigated the effects of miR-200
family on pancreatic CSC functions in this study. We
identified a highly tumorigenic subpopulation of pancre-
atic cancer cells expressing the cell surface markers
CD24, CD44 and ESA in pancreatic adenocarcinoma cell
line PANC-1. And CD24+CD44+ESA+ cells in PANC-1
were sorted by BD FACS Aria II for further study. Then,we analysed the miR-200 family and transcription factors
Oct4 and Nanog expression in CSCs of pancreatic can-
cer cell line PANC-1, and determined their relationships
with EMT markers and repressors of E-cadherin tran-
scription. In order to study the role of miR-200a for
EMT in CSCs, miR-200a mimic was transformed into
CSCs. In addition, invasion and metastasis were deter-
mined in CSCs and transformed CSCs.
Methods
Cell culture
Human pancreatic adenocarcinoma cell line, PANC-1
(Chinese Academy of Sciences, Shanghai, P.R. China)
was cultured in DMEM supplemented with 10% fetal bo-
vine serum (FBS), 100 U/ml penicillin G, and 100 Ug/ml
streptomycin. After sorting, cancer CSCs from the cell
line were cultured in either Celprogen’s pancreatic CSC
medium or DMEM-F12 supplemented with 1% N2 Sup-
plement (Invitrogen), 2% B27 Supple-ment (Invitrogen),
20 ng/ml human platelet growth factor (Sigma-Aldrich),
100 ng/ml epidermal growth factor (Invitrogen) and 1%
antibiotic-antimycotic (Invitrogen) at 37°C in a humidi-
fied atmosphere of 95% air and 5% CO2.
Flow cytometry
Dissociated cells were counted and transferred to a 5 ml
tube, washed twice with PBS, counted and resuspended
in PBS at 1 × 106 cell/100 μl. Then, the antibodies APC
anti-human CD44 (Becton Dickinson, USA), PE anti-
human CD24 (Becton Dickinson, USA) and FITC anti-
human ESA (Becton Dickinson, USA) (each at a dilution
of 1: 40) were added and incubated for 20 min on ice in
dark. The respective isotype control antibodies were
used at the same concentrations according to the manu-
facturer’s instructions. After washing twice with PBS,
samples were resuspended in 500 μl PBS and analyzed
on a flow cytometer (FACSAriaII, USA). Side-scatter and
forward-scatter profiles were used to eliminate cell dou-
blets. Cells were routinely sorted twice, and the cells
were reanalyzed for purity, which typically was > 97%.
Data were analyzed with BD FACS Diva software.
MiR-200a mimic transfection
The PANC-1 cells and CD24+CD44+ESA+ populations
of PANC-1 cells were plated in 6 well plates and incu-




at a final concentration of 25 nM using EntransterTM-R
transfection reagent (Engreen). After 6 h of transfection
the medium was changed to avoid cell death during trans-
fection. Control and miR-200a mimic were purchased from
Invitrogen.
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Total RNA was extracted using Trizol (Invitrogen) ac-
cording to the manufacturer’s instructions. For mRNA
analysis, real-time PCR was performed using Power
SYBR_ green PCR master mix (Applied Biosystems) on
an ABI 7500 series PCR machine Applied Biosystems,
and data were normalized to GAPDH expression and
further normalized to the negative control unless other-
wise indicated. Custom primers for E-cadherin, N-
cadherin, vimentin and ZEB1, Oct4 and Nanog were





vimentin forward primer 5′-CCTTGAACGCAAAGTG
GAATC-3′, reverse primer 5′-TGAGGTCAGGCTTG
GAAACAT-3′; ZEB1 forward primer 5′-GGAATGTA
TGCTTGTGATTTGTG-3′, reverse primer 5′-CTCTC
TTACAGTAGGAGTAGCGATG-3′; Oct4 forward primer





Total RNA was reverse transcribed using the miScript
Reverse Transcription Kit (Qiagen, Valencia, CA). RT-
qPCR was performed using the miScript PCR Kit
(Qiagen). Experiments were normalized to U6. Results
were reported as RQ with respect to a calibrator sample
using the 2-ΔΔCt method. MiR-200a, miR-200b, miR-
200c and U6 kits were purchased from Biomics biotech
(NanTong).
Western blot analysis
Cells were lysed in RIPA lysis buffer and the protein
concentration was determined. Total proteins were frac-
tionated using SDS-PAGE and transferred onto a polyvi-
nylidene fluoride membrane. The membranes were
blocked in 5% skim milk in TBST buffer containing 0.1%
Tween 20 and then incubated with indicated primary
antibodies (Rabbit anti-N-cadherin, 1: 1000, Millipore;
Mouse anti-Vimentin, 1: 500, Millipore; Rabbit anti-E-
cadherin, 1: 1000, Abgent; Rabbit Anti-ZEB1, 1: 1000,
Cell Signaling) for 2 h at room temperature. HRP-
conjugated secondary antibodies (HRP Goat anti-Rabbit
IgG Antibody, 1: 5000, Abgent; HRP Goat anti-Mouse
IgG Antibody, 1: 5000, Abgent) were incubated at room
temperature (RT) for 1 h and detected using the enhanced
chemiluminesence detection system.Total protein was
extracted from untreated and the cells treated by trans-
fecting miR-200a and subjected to western blot analysis
as described to evaluate the expression of E-cadherin,N-cadherin, ZEB1 and vimentin. The data was adjusted
against loading control using β-actin.
Transwell migration assay
For transwell migration assays, 1 × 105 pancreatic CSCs
were plated in the top chamber onto the noncoated
membrane (24-well insert; pore size, 8 mm; Corning
Costar) and allowed to migrate toward serum-containing
medium in the lower chamber. Cells were fixed after 48
hours of incubation with methanol and stained with 0.1%
crystal violet (2 mg/mL, Sigma-Aldrich). The number of
cells invading through the membrane was counted under a
light microscope (three random fields per well).
Transwell invasion assay
For invasion assay, 1 × 105 cells were plated in the top
chamber onto the Matrigel coated Membrane (24-well
insert; pore size, 8 μm; Corning Costar). Each well was
coated freshly with Matrigel (60 mg; BD Bioscience) be-
fore the invasion assay. Cells were plated in medium
without serum or growth factors, and medium supple-
mented with serum was used as a chemo-attractant in
the lower chamber. The cells were incubated for 48
hours and cells that did not invade through the pores
were removed by a cotton swab. Cells on the lower sur-
face of the membrane were fixed with methanol and
stained with crystal violet. Thenumber of cells invading
through the membrane was counted under a light micro-
scope (three random fields per well).
Statistical analyses
All values were expressed as means ± S.E.M. The statis-
tical significance of differences among groups was deter-
mined by a one-way analysis of variance (ANOVA)
followed by the Tukey’s post hoc multiple comparison
tests. A P < 0.05 was considered significant. Each experi-
ment consisted of at least three replicates per condition.
All statistical analyses were conducted with a STATA
7.0 software package (Stata Corp, College Station, TX)
experiments.
Results
Isolation and characterization of human pancreatic CSCs
Flow cytometric analysis was used to determine the
presence of CD44, CD24 and ESA on the cell surface
of the pancreatic adenocarcinoma cell lines PANC-1
(Figure 1A and B). In PANC-1, 0.7%-2.2% of cells were
CD44+CD24+, and 0.1%-0.9% of cells were CD44+
CD24+ESA+. The morphology of PANC-1 cell line and
CD44+CD24+ESA+ CSCs were shown in (Figure 1C
and D). CD44+CD24+ESA+ CSCs formed spheroid in
CSC medium× 200 magnification (Figure 1D). Nanog and
Oct4 are required for the maintenance of pluripotency in
embryonic stem cells and induce cancer stem cell–like
Figure 1 Presence of CD44, CD24 and ESA on cell surface in pancreatic carcinoma cell line PANC-1. Flow cytometric analysis was used to
determine the presence of CD44, CD24, and ESA on the cell surface of pancreatic adenocarcinoma cell line PANC-1. (A) The presence of CD44+CD24+
population (Q2) of PANC-1 cell line. (B) The presence of CD44+CD24+ESA+ population (P2) of PANC-1 cell line. The morphology of PANC-1 cell line
(C) and CSCs (D) (Scale bar = 50 μm). (E)The expressions of Oct4 and Nanog were measured by real-time PCR in PANC-1 and CSCs. Data represent
mean ± SD. * = significantly different from PANC-1, P < 0.05, ** = significantly different from PANC-1, P < 0.001.
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of CD44+CD24+ESA+ cells, real time-PCR was used to
determine the expressions of transcription factors Oct4
and Nanog in CSCs. The results showed that Oct4 and
Nanog expressions were significantly increased in CSCs
(Figure 1E).
MIR-200a and EMT markers expression in CSC of PANC-1
MiR-200 family is known as tumor suppressor and they
are usually down-regulated in EMT in some cancer stem
cells, such as in prostate cancer and breast cancer
[22,23]. MiR-200/ZEB2 pathway in mesenchymal-to-
epithelial transition and induced pluripotent stem cell
generation [24]. We determined the expression levels of
miR-200a, miR-200b and miR-200c in PANC-1 cell line
and CSCs by real time-PCR. Real time-PCR result
showed that miR-200a were significantly downregulated
in CSCs (Figure 2A), while miR-200b and miR-200c ex-
pressions were similar with PANC-1 cell line (data was
not shown). EMT is accompanied by E-cadherin down-
regulation and N-cadherin up-regulation. We found the
expressions of N-cadherin, vimentin and ZEB1 were up-
regulated, while the expression of E-cadherin exhibited
down-regulation at mRNA levels in CSCs of pancreatic
cancer cell line PANC-1. These results suggested thatCSCs showed EMT characteristics which was defined by
the expression of specific miRNA and its target genes
(Figure 2B).
MIR-200a regulated EMT of CSCs in pancreatic cancer
Members of miR-200 family are known to be tumor
suppressors, which are usually downregulated in some
tumors. Down-regulation of miR-200 by siRNA tech-
nique has been shown to be associated with EMT
phenotype while overexpression of miR-200a can re-
sult in the reversal of EMT phenotype [22]. To inves-
tigate the role of miR-200a in the reversal of EMT
phenotype of CSCS, we transfected miR-200a mimics
or non-specific control miRNA mimic (NC mimic) into
CSCs (Figure 3A). We found that the overexpression
of miR-200a in the CSCs resulted in the up-regulation
of epithelial marker E-cadherin and down-regulation of
mesenchymal markers ZEB1, N-cadherin and Vimentin
at mRNA level (Figure 3B). These results suggest that
the loss of miR-200a is critical for the acquisition of
EMT characteristics and that the overexpression of
miR-200a could reverse the EMT phenotype of CSCs.
After transfection, the morphology of miR-200a trans-
fected CSCs was partially changed from elongated fibro-
blastoid to epithelial cobblestone-like appearance, and the
Figure 2 miR-200a and EMT markers expression in CSCs of PANC-1. (A) Real-time PCR analyzed the expression of miR-200a in PANC-1 and
CSCs. (B) Real-time PCR analyzed the expression of E-cadherin, N-cadherin, ZEB1 and vimentin in PANC-1 and CSCs. Data represent
mean ± SD. * = significantly different from PANC-1, P < 0.05, ** = significantly different from PANC-1, P < 0.001.
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(× 200 magnification) (Figure 3C-E). By westernblot
analysis, we found that the overexpression of miR-200a
in the CSCs resulted in the up-regulation of epithelial
marker E-cadherin and down-regulation of mesenchymal
markers ZEB1 and N-cadherin, but not Vimentin at pro-
tein level (Figure 4A and 4B).Figure 3 miR-200a regulated EMT of CSCs in pancreatic cancer. (A) M
CSCs of PANC-1 resulted in up-regulation of E-cadherin and down-regulated e
(C-E) The morphology of CSCs changed from sphericity to epithelial-like appea
(D) CSCs transfected by control mimic and (E) CSCs transfected by miR-200a
different from control, P < 0.05, ** = significantly different from control, P < 0MiR-200a overexpression decreased the ability of
invasion and migration of CSCs
EMT induction in cancer cells results in the acquisition
of invasive and metastatic properties [25]. To evaluate
the invasive and migration potential of miR-200 overex-
pression CSCs, an assay was performed using Transwell
inserts. The results showed that the number of CSCsiR-200a mimic was efficient in CSCs. (B) Overexpression of miR-200a in
xpression of N-cadherin, ZEB1 and vimentin as assessed by Real-Time PCR.
rance after miR-200a transfection. (C) The morphology of CSCs control,
mimic (Scale bar = 50 μm). Data represent mean ± SD. * = significantly
.001. Data represent mean ± SD.
Figure 4 miR-200a induced MET in human pancreatic CSCs. (A) Western blot analysis showed the expression of E-cadherin was up-regulated
and the expression of ZEB1 and N-cadherin was down-regulated in CSCs transfected by miR-200a mimic. (B) Quantification of immunoblot data.
Data represent mean ± SD. * = significantly different from control, P < 0.05, ** = significantly different from control, P < 0.001.
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grated to the lower side of the membrane was signifi-
cantly decreased than CSCs or NC mimic by about 0.33
fold in invasion and 0.22 fold in migration, respectively
(Figure 5). These results clearly suggested that overex-
pression of miR-200a inhibits migration and invasion
of CSC cells through the reversal of EMT to MET
phenotype.
Discussion
Pancreatic cancer is the fourth to fifth leading cause of
cancer-related death in western societies with an average
overall 5-year survival of less than 5% and a median sur-
vival period of less than 6 months [26]. CSCs are a small
subpopulation of cells capable of self-renewal and differ-
entiation and have been identified in a variety of tumors.
CSCs may be responsible for tumor initiation, progression,
metastasis and resistance to therapy. The expression pat-
terns of the stem cell surface markers CD44, CD24 and
ESA in pancreatic adenocarcinoma cell lines are diverse
and not all CSCs sorted from pancreatic adenocarcinoma
cell lines develop cell spheres [27], PANC-1 is a common
pancreatic adenocarcinoma cell line used for study of CSCs
[28-32]. In this study, we sorted CD44+CD24+ESA+ CSCs
in pancreatic adenocarcinoma cell line PANC-1. Stem cell
features are controlled by a small group of transcription
factors, like Nanog and Oct4 [33]. Coexpression of Oct4
and Nanog is associated with pancreatic carcinogenesis
and is negatively correlated with the survival prognosis of
oral squamous cell carcinoma patients [34]. Oct4 and
Nanog induce cancer stem cell–like properties and have
correlations with EMT [35]. Our study also demonstrates
that the expressions of Oct4 and Nanog were increased in
CSCs of PANC-1.Emerging evidence suggests the role of microRNA
(miRNA) in many biological processes. Among many
miRNAs, miR-200 family is known as tumor suppressor
and they are usually down-regulated in some tumors in-
cluding prostate cancer and the loss of expression of
miR-200 family contributes to the acquisition of EMT
phenotype and drug resistance. Down-regulation of miR-
200 by siRNA technique has been shown to be associated
with EMT phenotype while reexpression of miR-200 can
result in the reversal of EMT phenotype. We determined
the expression levels of miR-200a, miR-200b and miR-200c
in CSCs of PANC-1 by real time RT-PCR. Among the fam-
ily of miR-200, only miR-200a expression was dramatically
decreased.
EMT induction in cancer cells results in the acquisi-
tion of invasive and metastatic properties. Recent reports
indicate that the emergence of CSCs occurs in part as a
result of EMT, for example, through cues from tumor
stromal components. CSCs and EMT-type cells, which
shares molecular characteristics with CSCs, have been
believed to play critical roles in drug resistance and early
cancer metastasis as demonstrated in several human ma-
lignancies including pancreatic cancer. Interestingly, re-
cent studies have also shown that miR-200 family could
regulate the processes of EMT by targeting E-box bind-
ing protein ZEB1 and ZEB2 [36]. Thus, the discovery of
molecular knowledge of drug resistance and metastasis
in relation to miR-200 family, CSCs and EMT in pancre-
atic cancer are becoming an important area of research,
and such knowledge is likely to be helpful in the discov-
ery of newer drugs as well as designing novel therapeutic
strategies for the treatment and/or prevention of pancre-
atic cancer with better outcome. E-cadherin, occludin
and cytokeratin are downregulated during EMT, while
Figure 5 miR-200 reduces invasion and migration in human pancreatic cancer. The number of cells invasion and migration in the miR-200a
mimic treated groups were decresed (A-F). (A and D) CSCs control, (B and E) NC mimic, (C and F) miR-200a mimic, (A-C) the number of cells
invasion and (D-F) the number of cells migration. (G and H) Quantification of invasion and migration data. Data represent mean ± SD. * = significantly
different from control, P < 0.05, ** = significantly different from control, P < 0.001 (Scale bar = 50 μm).
Lu et al. BMC Cancer 2014, 14:85 Page 7 of 9
http://www.biomedcentral.com/1471-2407/14/85N-cadherin, vimentin, fibronectin, SNAI1/SAIL, SNAI2/
SLUG, ZEB2/SIP1, and TWIST1 are upregulated class
switch from E-cadherin to Ncadherin results in the loss
of epithelial phenotype and the acquisition of mesenchy-
mal phenotype. Transcriptional repression of E-cadherin
gene or functional repression of E-cadherin protein is
the critical step for EMT. Upregulation of EMT regula-
tors is associated with more malignant phenotypes in a
variety of human cancer, such as gastric cancer, pancre-
atic cancer, breast cancer, and ovarian cancer [37]. In the
present study, miR-200a inhibits epithelial-mesenchymal
transition by inhibiting the expression of vimentin,
N-cadherin and ZEB1, and also retards CSCs migration
and invasion. The inhibition of EMT markers by these
agents suggests that they could inhibit early metastasis of
pancreatic CSCs.
The EMT is an embryonic key developmental program
that is often activated during cancer invasion and metasta-
sis. It is a process by which cells undergo a morphological
switch from the epithelial polarized phenotype to the
mesenchymal fibroblastoid phenotype. Many signallingpathways have contributed to the induction of EMT,
including TGFβ-1, Wnt, Hedgehog, Notch, and nuclear
factor-kappa B (NF-kB) [38-42]. Kyoung-Ok Hong et al.
have shown that activation of PI3K/Akt axis is one of the
key mechanisms in the process of EMT and it seems that
its inhibition by treatment with phosphatidylinositol ether
lipid analogues (PIA) may regulate the reverse process
MET leading to the re-expression of both E-cadherin and
β-catenin, and reducing expression of vimentin, mesenchy-
mal marker, in oral squamous lines carcinoma stabilized
[43]. Further stuty was needed to probe the signalling path-
ways participatived in MET of CSCs.
Conclusion
In summary, we identified a highly tumorigenic subpop-
ulation of pancreatic cancer cells expressing the cell
surface markers CD24, CD44 and ESA in pancreatic
adenocarcinoma cell line PANC-1. MiR-200a played
important roles in the MET process of CSCs by chan-
ging EMT markers expressions and cell migration and
invasion. Thus, further studies are needed to elucidate
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ing EMT phenotypic cells and to assess whether miR-
200a could be useful for the prevention of pancreatic
cancer tumorigenesis and metastasis.
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